Recurrent Squamous Cell Carcinoma of the Larynx Completed Phase 2 Trials for Saracatinib (DB11805)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00513435Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerTreatment